key: cord-0922870-as7wj0hi
authors: Gale, Robert P.
title: Perspective: Cell therapy, SARS‐CoV‐2, COVID‐19, and James Lind
date: 2020-05-21
journal: Adv Cell Gene Ther
DOI: 10.1002/acg2.88
sha: b50174d01761b4d563b5bcae2f97344b4dd996b4
doc_id: 922870
cord_uid: as7wj0hi

nan

in persons with hematological cancers. My Chinese colleagues and I studied several aspects of this in Wuhan, epi-center of the SARS-CoV-2 pandemic and in Hubei province. In one study in > 500 persons with chronic myeloid leukemia (CML), we found only five cases of COVID-19. 4 Although this case rate was substantially higher than the case rate in normals in Hubei province, it is obviously not a serious issue in persons with CML. Risk factors included exposure to someone infected with SARS-CoV-2, no complete hematological remission (CHR), initial presentation as advanced leukemia despite responding to therapy and, possibly, receiving a third-generation tyrosine kinase inhibitor (TKI).

In another study we compared > 100 hospitalized persons with hematological disorders in two hospitals in Wuhan to similar numbers of healthcare providers in the same hospitals. We found similar COVID-19 case rates, about 10%, but a much higher case fatality rate in the hospitalized hematology patients, about > 60%. We were unable to identify prognostic or predictive covariates in the hematology patients for developing or dying from COVID-19 suggesting the need for careful infection surveillance and possible protective isolation. 5 In the third study, we sought to determine safety and efficacy 

None.

I confirm adhering to the ethical policies of the journal noted on the journal author guidelines page. No ethical approval was required for this Perspective article with no original research data. However, I advise against drinking diluted sulfuric acid.

https://orcid.org/0000-0002-9156-1676

A review of cancer immunotherapy toxicity

Tocilizumab treatment in COVID-19: a single center experience

Possible role of mesenchymal stromal cells in coronavirus infectious disease-19-related severe acute respiratory syndrome

COVID-19 in persons with chronic myeloid leukaemia

COVID-19 in persons with haematological cancers

Evidence against use of corticosteroids SARS-CoV-2, SARS-CoV and MERS-CoV infections

Recommendations for hematopoietic stem cell transplantation during the COVID-19 outbreak: experience and perspective from China

How to cite this article: Gale RP. Perspective: Cell therapy, SARS-CoV-2, COVID-19